These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33507738)

  • 1. Drug Safety Data Curation and Modeling in ChEMBL: Boxed Warnings and Withdrawn Drugs.
    Hunter FMI; Bento AP; Bosc N; Gaulton A; Hersey A; Leach AR
    Chem Res Toxicol; 2021 Feb; 34(2):385-395. PubMed ID: 33507738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals.
    Schick A; Miller KL; Lanthier M; Dal Pan G; Nardinelli C
    Drug Saf; 2017 Jun; 40(6):497-503. PubMed ID: 28342075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.
    Yeh JS; Sarpatwari A; Kesselheim AS
    Drug Saf; 2016 Aug; 39(8):709-14. PubMed ID: 27000800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing of new black box warnings and withdrawals for prescription medications.
    Lasser KE; Allen PD; Woolhandler SJ; Himmelstein DU; Wolfe SM; Bor DH
    JAMA; 2002 May; 287(17):2215-20. PubMed ID: 11980521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
    Beninger P; Murray M
    Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating drug repositioning opportunities in FDA drug labels through topic modeling.
    Bisgin H; Liu Z; Kelly R; Fang H; Xu X; Tong W
    BMC Bioinformatics; 2012; 13 Suppl 15(Suppl 15):S6. PubMed ID: 23046522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An analysis of legal warnings after drug approval in Thailand.
    Sriphiromya P; Theeraroungchaisri A
    Regul Toxicol Pharmacol; 2015 Feb; 71(1):108-13. PubMed ID: 25445000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.
    Kim J; Nair A; Keegan P; Beaver JA; Kluetz PG; Pazdur R; Chuk M; Blumenthal GM
    Oncologist; 2020 Apr; 25(4):348-354. PubMed ID: 32297444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ChEMBL: a large-scale bioactivity database for drug discovery.
    Gaulton A; Bellis LJ; Bento AP; Chambers J; Davies M; Hersey A; Light Y; McGlinchey S; Michalovich D; Al-Lazikani B; Overington JP
    Nucleic Acids Res; 2012 Jan; 40(Database issue):D1100-7. PubMed ID: 21948594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WITHDRAWN--a resource for withdrawn and discontinued drugs.
    Siramshetty VB; Nickel J; Omieczynski C; Gohlke BO; Drwal MN; Preissner R
    Nucleic Acids Res; 2016 Jan; 44(D1):D1080-6. PubMed ID: 26553801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classification of nervous system withdrawn and approved drugs with ToxPrint features via machine learning strategies.
    Onay A; Onay M; Abul O
    Comput Methods Programs Biomed; 2017 Apr; 142():9-19. PubMed ID: 28325450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The eTOX data-sharing project to advance in silico drug-induced toxicity prediction.
    Cases M; Briggs K; Steger-Hartmann T; Pognan F; Marc P; Kleinöder T; Schwab CH; Pastor M; Wichard J; Sanz F
    Int J Mol Sci; 2014 Nov; 15(11):21136-54. PubMed ID: 25405742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences between the United States and Japan in labels of oncological drugs.
    Jayaputra K; Ono S
    Pharmacoepidemiol Drug Saf; 2017 Feb; 26(2):143-151. PubMed ID: 27670850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA boxed warnings: how to prescribe drugs safely.
    O'Connor NR
    Am Fam Physician; 2010 Feb; 81(3):298-303. PubMed ID: 20112888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different black box warning labeling for same-class drugs.
    Panagiotou OA; Contopoulos-Ioannidis DG; Papanikolaou PN; Ntzani EE; Ioannidis JP
    J Gen Intern Med; 2011 Jun; 26(6):603-10. PubMed ID: 21286838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods.
    Zdrazil B; Felix E; Hunter F; Manners EJ; Blackshaw J; Corbett S; de Veij M; Ioannidis H; Lopez DM; Mosquera JF; Magarinos MP; Bosc N; Arcila R; Kizilören T; Gaulton A; Bento AP; Adasme MF; Monecke P; Landrum GA; Leach AR
    Nucleic Acids Res; 2024 Jan; 52(D1):D1180-D1192. PubMed ID: 37933841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bringing greater transparency to "black box" warnings.
    Buckley NA; Rossi S
    Clin Toxicol (Phila); 2011 Jul; 49(6):448-51. PubMed ID: 21824055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs.
    Garg V; Raisch DW; McKoy JM; Trifilio SM; Holbrook J; Edwards BJ; Belknap SM; Samaras AT; Nardone B; West DP
    Expert Opin Drug Saf; 2013 May; 12(3):299-307. PubMed ID: 23480866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.